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PERENCATAN SPESIFIK URUTAN GEN RNA MIKRO-130A 
MENGGUNAKAN CRISPR DALAM TITISAN SEL KANSER PARU-PARU 





Kanser paru-paru sel bukan kecil (NSCLC) adalah salah satu punca utama 
kematian di dunia dan insiden telah meningkat selama bertahun-tahun. Terapi semasa 
bergantung kepada radiasi dan kemoterapi, yang pada masa yang panjang akan 
memaparkan rintangan radiografi dan kemoterapi di lokasi kanser. Oleh itu, untuk 
meningkatkan kecekapan dan kekhususan dalam terapi kanser, strategi terapi yang 
disasarkan berdasarkan RNA mikro (miRNA) sedang dibangunkan. Beberapa kajian telah 
melaporkan bahawa miRNA memainkan banyak peranan dalam pelbagai tahap 
karsinogenesis kanser, dan boleh berfungsi sebagai alat terapeutik yang berpotensi untuk 
pengurusan kanser. Oleh itu, kajian ini bertujuan untuk mengkaji peranan miR130a dalam 
NSCLC dengan memanipulasi ungkapan miRNA menggunakan sistem ulangan 
palindromik (CRISPR)-Cas9 secara berkala. Bagi mencapai tujuan itu, 20 bp urutan RNA 
berpandu tunggal yang disasarkan pada gelung batang, 3 'dan 5' hujung miR130a direka 
dan diklonkan ke dalam plasmid lentiCRISPRv2. Klon positif telah disahkan oleh 
penjujukan dan transjangkitan masuk ke sel-sel A549 menggunakan Lipofectamine® 
3000 sebelum sel-sel transjangkitan stabil dipilih oleh puromycin. Keseluruhan RNA 
diekstrak dan tahap miR130a-3p dan miR130a-5p matang dikira menggunakan qRT-PCR 
menggunakan TaqMan Universal Master Mix (Applied Biosystems). Keputusan 
menunjukkan bahawa ekspresi miR130a-3p dan 5p secara signifikan dikurangkan kepada 
dua dan tiga kali ganda. Daya tahan sel telah dianalisis menggunakan ujian MTS dan 
ditunjukkan bahawa penurunan ekspresi miR130a-3p dan 5p secara signifikan 
merencatkan kebolehidupan sel tahan sel pada 24 dan 48 jam. Kesan proliferasi jangka 
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panjang oleh ujian pembentukan koloni dilakukan dan hasil menunjukkan penurunan 
ketara dalam proliferasi sel seperti yang ditunjukkan oleh penurunan jumlah dan saiz 
kolon. Oleh itu, keputusan menunjukkan bahawa sistem CRISPR-Cas9 boleh digunakan 
untuk menindas ungkapan miR130a-3p dan 5p matang  ke atas sel A549. MiRNA 
bertindak sebagai onkogen ke atas sel-sel A549 disebabkan oleh penurunan ekspresi 
tersebut telah menunjukkan penurunan kebolehidupan sel-sel A549 dengan signifikan. 
Untuk meramal fungsi peraturan miR130a, alat analisa bioinformatik gabungan dilakukan 
untuk mengenal pasti miR130a-3p dan 5p gen sasaran yang berpotensi. Analisis telah 
mengenal pasti sembilan gen sasaran yang diramalkan untuk miR130a-3p (RAPGEF4, 
SOS2, NRP1, RPS6KB1, MET, IL15, ACVR1, RYR2 and ITPR1), sepuluh untuk 
miR130a-5p (BCL11A, SPOPL, NLK, PPARGC1A, POU4F2, CPEB4, ST18, RSBN1L, 
ELF5 and ARID4B). Walau bagaimanapun, kajian-kajian hiliran yang lebih lanjut antara 
gen sasaran yang diramalkan dan miR130a adalah perlu untuk lebih memahami interaksi 
mereka. Kesimpulannya, kajian ini menunjukkan potensi terapeutik miR130a sebagai 
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Non-small cell lung cancer (NSCLC) is one of the main causes of mortality 
globally and the incidence has been rising over the years. Current therapies rely on 
radiation and chemotherapy, which over time exhibited radio-resistance and 
chemoresistance at the cancer site. Hence, to improve the efficiency and specificity in the 
cancer therapy, targeted therapeutic strategies based on microRNA (miRNA) are 
currently being developed. Several studies have reported that miRNA play roles in multi-
steps carcinogenesis of cancers, and may serve as potential therapeutic tools for cancer 
management. Therefore, this study aims to investigate the roles of miR130a in NSCLC 
by manipulating the expression of miRNA using the clustered regularly interspaced short 
palindromic repeat (CRISPR)-Cas9 system. To achieve the aim, 20 bp single-guided 
RNA sequences targeted at stem loop, 3' and 5' end of miR130a were designed and cloned 
into lentiCRISPRv2 plasmid. The positive clones were confirmed by sequencing and 
transfected to A549 cell line using Lipofectamine® 3000 before the stably transfected 
cells were selected by puromycin. Total RNA was extracted and the mature level of 
miR130a-3p and miR130a-5p were quantified using qRT-PCR using TaqMan Universal 
Master Mix (Applied Biosystems). Result showed that the expression of miR130a-3p and 
5p were significantly downregulated to two and three-fold respectively. Cell viability was 
analysed using MTS assay and it was shown that downregulation of miR130a-3p and 5p 
significantly inhibit cell viability at 24 and 48 hours. Long-term proliferation effect by 
colony formation assay was performed and result showed significant decrease in cell 
proliferation as exhibited by decrease number and size of colonies. Thus, result suggested 
that the CRISPR/Cas9 system can be used to suppress the expression of mature miR130a-
3p and 5p in A549 cell line. The miRNAs acted as oncogene in A549 cell line as 
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downregulation of them significantly suppressed the viability of A549 cell line. To 
predict the regulatory function of miR130a, combinatorial bioinformatics analyses tool 
was performed to identify potential target genes of miR130a-3p and 5p. The analyses 
have identified nine predicted target genes for miR130a-3p (RAPGEF4, SOS2, NRP1, 
RPS6KB1, MET, IL15, ACVR1, RYR2 and ITPR1), and ten for miR130a-5p (BCL11A, 
SPOPL, NLK, PPARGC1A, POU4F2, CPEB4, ST18, RSBN1L, ELF5 and ARID4B). 
However, further downstream studies between these predicted target genes and miR130a 
are necessary to further understand their interaction. In conclusion, this study has shown 













1.1 Background of the study 
Around 42 million people in the world has been estimated to suffer from any forms of 
cancer. In 2016, the highest prevalence of cancer are breast cancer with 8 million, colon 
and rectum with 6.3 million, prostate with 5.7 million and trachea, bronchus and lung 
cancer with over 2.8 million (Global Burden of Disease Collaborative Network, 2017). 
Although lung cancer does not rank as the highest in prevalence, it causes the highest 
mortality globally with 1.71 million which is more than double the number of the second 
ranked, stomach cancer (0.83 million) (Global Burden of Disease Collaborative Network, 
2017). Besides that, World Health Organisation (WHO) reported that trachea, bronchus 
and lung cancer ranked 6th in the top ten cause of death in the world with 23 crude death 
per 100 000 population (World Health Organisation, 2018b).  
 
Lung cancer is malignant tumour which starts in bronchial epithelium, bronchioles, 
alveoli, and bronchial glands (Zamay et al., 2017). WHO classified lung cancer into two 
main types which are small-cell lung cancer (SCLC) and non-small lung cancer 
(NSCLC). NSCLC attributed to 85% of lung cancer cases (Wood et al., 2018). 
Approximately only 13 – 15% of lung cancer patients survive within five years after 
diagnosis (Zamay et al., 2017). Detection at later stage causes them to spread from lung 
to central nervous system in 54% cases (Gaspar et al., 1997, Cho et al., 2005). Difficult 
for early detection and resistance towards available radiotherapy and chemotherapy 
contributes for high morbidity and mortality in lung cancer cases (Sato et al., 2007).   
 
Most lung cancer cases were detected at an advanced stage when it has already 
metastasised, and only when symptoms such as coughing, coughing up blood, chest pains 
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and shortness of breath developed (Hirsch et al., 2017).  Patient with earlier stage is 
suggested to undergo surgery (Hirsch et al., 2017). Radiotherapy and chemotherapy were 
carried out for patient with medical contraindications for surgery, for patient who refuses 
surgery and for advanced stage lung cancer patient (Hirsch et al., 2017). However, current 
radiotherapy and chemotherapy have been shown to exhibit resistance. Thus, targeted 
therapy for specific molecular genomics alteration may be a better therapy option for 
patient. To support, a recent study by Merck revealed that in comparison to 
chemotherapy, pembrolizumab, programmed cell death 1 (PD-1) inhibitor increases 
survival benefit for patients with PD-L1-expressing tumours in NSCLC (Kenilworth, 
2016). In addition, a study suggested an effective targeted agent in conjunction with 
radiotherapy and chemotherapy for locally advanced NSCLC patient is needed to increase 
the survival rate of patient (Hirsch et al., 2017). Hence, targeted therapy on molecular 
genomic alteration will improve the efficiency and specificity in lung cancer therapy.  
 
The current therapy rarely cure the cancer as the survival rate within 5 years is only 15% 
(Sato et al., 2007).  Thus, there is an important need for new tools which use the 
knowledge about specific molecular targets and the pathogenesis of lung cancer (Fong et 
al., 1999). These tools need to address on how the tumour cell is regulated by oncogenes 
and tumour suppressor genes by causing uncontrollable proliferation and metastasis via 
disruption of important cell-cycle regulators and cascades of signal transduction (Fong et 
al., 1999). Currently, only two genetic abnormalities namely epidermal growth factor 
receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) gene rearrangements 
were developed with targeted therapies (Hirsch et al., 2017). Therefore, specific and 
highly sensitive reliable biomarkers and personalised molecular targeted therapies are 
important to increase specificity of treatment as well as to increase the survival rate of the 




In order to investigate the target molecular activity of genes, selection of precise and 
efficient gene editing technique is important. One of the genome editing technology, 
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) system is 
increasingly being employed to silence protein-coding genes in several model organisms 
(Ran et al., 2013). CRISPRs are DNA loci with short repetitions of base sequences 
(Marraffini and Sontheimer, 2010). Cas9 is nuclease guided by small RNAs introduces 
dsDNA cleavage at targeted genomic locus (Ran et al., 2013). Cas9 reduce the off-target 
effect as it is highly specific, efficient and well-suited for high throughput and multiple 
gene editing for different cell types and organisms (Ran et al., 2013, Mali et al., 2013). 
However, the use of this CRISPR-Cas9 technologies need to be further investigated at 
both pre-clinical and clinical level to study the safety, specificity and efficiency of the 
system in lung cancer targeted therapy. 
 
In this study CRISPR-Cas9 systems is used to increase the understanding of regulation 
and function of miR130a in NSCLC cell line. MicroRNAs (miRNAs) are short stranded 
noncoding RNA of ~22 nucleotides that participates in various human biological 
activities such as regulation of apoptosis, cell proliferation, cellular differentiation, 
development and immune responses (He and Hannon, 2004). In cancer cells, several 
studies have shown that miRNAs have an ability to distinguished malignant cancer cells 
from normal and play a role in the carcinogenesis development in cancer patients giving 
high hope to use miRNAs as biomarker for diagnosis, prognosis and treatment of cancer 
(Li et al., 2008, Wang et al., 2014, Nurul-Syakima et al., 2011, Chen et al., 2009). The 
miR-130a has been reported to be upregulated in several types of cancer, such as colon 
cancer, chronic myeloid leukaemia and hepatocellular carcinoma indicating the important 
roles of miR130a in cancer development, progression and metastasis (Chen et al., 2010, 
Wang et al., 2010, Suresh et al., 2011, Zhou et al., 2012). Thus, the role of miR130a need 
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to be extensively studied at in vitro level first in order to understand the regulatory 
function of miR130a in lung cancer. 
 
Association between miRNAs and target genes can be predicted using several miRNA 
prediction databases. The bioinformatics platforms have been used to analyse large 
amount of data and to perform comparative analysis of differentially expressed genes. 
Comparative studies of the earlier miRNA target prediction programs proved that there 
were no program that constantly better than all others (Rajewsky, 2006, Sethupathy et al., 
2006). The platforms may be used together to complement each other in order to achieve 
the objective of predicting the target genes of miR130a. Hence, in this study, three 
bioinformatics platforms namely miRWalk, the Database for annotations, visualization 
and integrated discovery (DAVID) Gene Functional Classification Tool and miRanda-
miRSVR analysis tools were used to identify possible interaction between miR130a and 
















1.2 Problem statement 
NSCLC has been attributed to largest cases to lung cancer patients. Thus, development 
of specific and highly sensitive new targeted therapies is important to improve current 
therapies as well as to increase the survival rate of the advanced stage lung cancer 
patients. miR130a has been shown to play important role in carcinogenesis of lung cancer. 
However, the role of miR130a is not well documented in NCSLC. One of the ways to 
study the function of miR130a in NSCLC is by gene manipulation by silencing the 
expression of miR130a. Gene manipulation can be performed by several means, and that 
includes the genome editing technology, CRISPR-Cas9 system. However, the efficiency 
and specificity of CRISPR-Cas9 system in silencing the expression of miRNA is poorly 
studied. Hence, in this study, CRISPR-Cas9 system will be implemented to silence the 
expression of miR130a in NSCLC cell line. This CRISPR-Cas9-miRNA system may 
assist in understanding the multistep mechanisms of miR-130a regulatory activities in 
NSCLC. Besides that, in order to identify the target gene of miR130a in pathways 
involved, three bioinformatics platforms namely miRWalk, DAVID gene functional 
classification tool, miRanda-miRSVR analysis tool were employed for gene prediction 
analysis of miR130a-3p and 5p and STRING database for protein-protein interaction 












1.3 Research objective 
The ultimate objective of this study is to investigate the role of miR130a by knocking-
down the expression of miR130a using CRISPR-Cas9 system, and to predict associations 
between miR130a and target genes by bioinformatics analyses.  
 
1.3.1 Specific objectives: 
i. To design single guide RNA targeting at the miR130a gene and to clone in the 
CRISPR Nuclease Vector. 
ii. To establish stable miR130a suppression in A549 cancer cell line. 
iii. To investigate the effects of miR130a suppression on viability and proliferation 
of A549 cell line. 




The CRISPR/Cas9 system could be used to stably silence the expression of miR130a. 
Silencing of miR130a affect the oncogenic properties of the A549 cell line particularly in 
the regulation of cell viability and cell proliferation. The bioinformatics analyses will 
identify potential target genes of miR130a, and predict the association between miR130a 
















Cancer is a main global public health problem. According to the World Health 
Organisation (WHO), 8.8 million deaths in 2015 is caused by cancer (World Health 
Organisation, 2018a). One in every six deaths worldwide is caused by cancer, making it 
the second highest cause of death in the world (Naghavi et al., 2017). Similarly, cancer is 
also a major health problem and the leading cause of death in Malaysia. Recently, 
Department of Statistics Malaysia reported that cancer ranked as the top five principal 
cause of death in 2016 (Department of Statistics Malaysia, 2017). Cancer is a large group 
of diseases which caused by a rapid growth of abnormal cells that have potential to spread 
to other organs via blood or lymph systems (World Health Organisation, 2018a). It can 
start almost anywhere in the body due to the interaction between genetic factors and 
external agents. External agents can be categorised into physical carcinogens (e.g. 
ultraviolet and ionising radiation), chemical carcinogens (e.g. asbestos, components in 
tobacco smoke) and biological carcinogens (e.g. infections from certain viruses, bacteria 
or parasites) (World Health Organisation, 2018a).  
 
There are over 200 types of cancers identified so far (World Health Organisation, 2018a). 
National Cancer Institute has categorised them under general names which are carcinoma, 
sarcoma, leukaemia, lymphoma and myeloma and central nervous system cancer 
(National Cancer Institute, 2015). Carcinoma is cancer that starts in the skin or in tissue 
that cover internal organs. Sarcoma on the other hand is cancer which starts in bone, 
cartilage, fat, muscle, blood vessels or other connective or supportive tissue. Cancer of 
blood is known as leukaemia while lymphoma and myeloma are cancers which starts in 
cells of the immune system. Lastly, cancer which begins in the tissue of the brain or spinal 
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cord such as brain and spinal cord tumours are known as central nervous system cancers 
(National Cancer Institute, 2015). Statistics from the Institute for Health Metrics and 
Evaluation (IHME) and Global Burden of Disease showed that the four leading types of 
cancer are breast cancer, colon and rectum cancer, prostate cancer, and tracheal, bronchus 
and lung cancer (Figure 2.1). 
 
 
Source: IHME and Global Burden of Disease (2017) 
Figure 2.1: World cancer incidence in 2016 among men and women in all age groups 
(Global Burden of Disease Collaborative Network, 2017).  
 
2.2 Lung cancer 
Lung cancer is the major cause of mortality and morbidity globally with 1.71 million 
deaths in 2016 (Figure 2.2) (Naghavi et al., 2017). The incidence of lung cancer deaths 
is expected to increase until 2030 unless efforts for worldwide tobacco control are 
prominently increased (Wood et al., 2018). In 2014, WHO reported that lung cancer 
recorded for 19.1 deaths per 100,000 population in Malaysia or 4,088 deaths per year 
(3.22% of all deaths) (World Health Organisation, 2018a). In addition, malignant 
neoplasm of trachea, bronchus and lung was also ranked as top five leading cause of death 
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in Malaysia in 2016 which showed that lung cancer is the most common cause of deaths 
in Malaysia (Department of Statistics Malaysia, 2017).  
 
 
Source: IHME and Global Burden of Disease (2017) 
Figure 2.2: World mortality numbers in different types of cancer in 2016 among men and 
women in all age groups (Global Burden of Disease Collaborative Network, 2017). 
 
2.2.1 Types of lung cancer  
Lung cancer is an uncontrolled growth of abnormal cell in tissues of the lung. It can be 
metastasised into nearby tissues or other parts of body. Most cancers which start in lung 
(primary lung cancers) are categorised as carcinomas (National Cancer Institute, 2015). 
WHO divided lung cancer based on its biology, therapy and prognosis. Two major classes 
of lung cancer are small cell lung cancers (SCLC) and NSCLC, and about more than 85% 
of lung cancer cases were attributed to NSCLC (American Cancer Society, 2017). There 
are three different types of NSCLC namely adenocarcinoma, squamous cell carcinomas 
and large cell carcinomas which are segregated based on the type of cells found in the 
tumour (Wood et al., 2018). Adenocarcinoma is the most common type and it starts in the 
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mucus making gland cells in the lining of airways (American Cancer Society, 2017). 
Squamous cell carcinoma on the other hand starts in even and smooth cells surface which 
cover the external layer of airways and have a tendency to grow near the centre of lung 
(American Cancer Society, 2017). Cancer cells which is large and round when observed 
under microscope is categorised as large cell carcinomas (American Cancer Society, 
2017). In lung cancer, lack of reliable markers, sensitive tools and poor prognosis 
contribute to poor early diagnosis and patient care (Ludwig and Weinstein, 2005). 
 
2.2.2 Diagnostic tests to screen for lung cancer 
Cigarette smoking is the main risk factor for development of lung cancer as nearly half 
of reported cases are diagnosed in former smoker (Wood et al., 2018, Sato et al., 2007). 
Therefore, identifying former smoker has been a crucial part in determining the highest 
risk individual to develop lung cancer (Sato et al., 2007). It is important to note that most 
cases were often detected by accident and first noticed at advanced stages when the 
cancers have already spread widely (Sato et al., 2007, Zamay et al., 2017). Efficient early 
detection method is important as it may help in earlier treatment of patient. Sputum 
cytology, chest x-ray and computer tomography (CT) scan has been used to screen for 
lung cancer (American Cancer Society, 2017). Currently, new diagnostic tests such as 
polymerase chain reaction (PCR), next-gene sequencing and florescent in-situ 
hybridisation have been employed for a better and precise screening for specific lung 
cancer genomic abnormalities (Hirsch et al., 2017).  Previous studies have reported that 
the development of lung cancer is from a multi-stage carcinogenesis of normal epithelial 
cells which are caused by genetic and epigenetic abnormalities, usually coupled with 
cigarette smoking (Zöchbauer-Müller et al., 2002, Sato et al., 2007). Currently, there are 
no one reliable therapy for different stages of lung cancer (Sato et al., 2007).  Thus, novel, 
highly sensitive and specific molecular gene target are crucial for therapy in different 




2.3 Current therapy for lung cancer 
The recommended treatment for patients with NSCLC (stage I and II) are surgery (Cao 
et al., 2012). Recently, molecular targeted therapies have been a great help for the 
treatment of advanced lung cancer patient, specifically the one with specific genomic 
abnormalities (Hirsch et al., 2017). A study stated that about 69% of patient with 
advanced lung cancer stage may have a potentially genomic molecular target (Tsao et al., 
2016). Figure 2.3 shows the targeted therapies for specific molecular features of genomic 
abnormalities (Hirsch et al., 2017).  The most common Epidermal Growth Factor 
Receptor (EGFR) mutations in NSCLC patients are deletions in exon 19 and mutations 
in exon 21 which results in the activation of the tyrosine kinase domain. The approved 
drugs which act as tyrosine kinase inhibitors (TKI) are erlotinib, gefitinib and afatinib 
(Langer, 2013). Another genomic aberration with approved drugs is anaplastic lyphoma 
kinase (ALK) gene rearrangements.  There are about 2 to 7 percent of NSCLC patients 
with the ALK rearrangements (Douillard et al., 2014). They have some comparable 
clinical characteristics to patients with EGFR mutations but resistant to EGFR TKIs 
(Ettinger et al., 2017). The approved drugs for patients with ALK rearrangements are 
crizotinib, which is an inhibitor for ALK, receptor tyrosine kinase 1 (ROS1) and some 
mesenchymal-epithelial transition factor (MET) tyrosine kinase. Patients whose disease 
progress with crizotinib will be given alectinib as a second option (Kim et al., 2016, 
Cheng and R Ott, 2010). Certinib also act as TKI of ALK which also inhibits insulin-like 
growth factor 1 (IGF-1) receptor (Ettinger et al., 2017). Currently, there are no approved 
drugs for the other genomic mutations listed in Table 2.1 besides EGFR mutations and 
ALK rearrangements.  As current standard drugs only give a modest survival benefits, a 
personalised drugs are better suited to molecular phenotypes of each individual which 
may increase the survival rate of patient with lung cancer (Sato et al., 2007). 
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 Molecular features Diagnostic tests Approved drugs 
Mutations EGFR  >90% exon 19 deletions and exon 21  
Activating mutations, exclusive of other driver aberrations; Thr790Met mutations are 
present in about half of the cases after tyrosine kinase inhibitor resistance 
PCR, next-generation 
Sequencing (mandatory in 






KRAS Codon 12 
(>90%), codon 13 

















Rearrangements  ALK Fusions of partner gene with exon 20 of ALK; partners in the 27 known fusion variants 
are EML4, KIF5B, TFG, and KLC1; exclusive of other driver aberrations 
FISH, 
immunohistochemistry 
(mandatory in non-SCC 





ROS1 Nine fusion proteins described with the FIG, SCL34A2, TPM3, SDC4, EZR, LRIG3, 
KDELR2, and CCDC6 genes; exclusive of other driver aberrations 
FISH, 
immunohistochemistry 
(recommended in EGFR 
and ALK with 
adenocarcinoma) 
None 
RET Fusions described with four partner genes: KIF5B, CCDC6, NCOA4, and TRIM33; 
exclusive of another driver 
Aberrations 
FISH None 
NTRK Fusions of NTRK1 and NTRK2 occur with a range of partners; NTRK3 fusions are rare FISH None 
Copy number gain MET Several definitions; 
preferable: MET:CEP7 
ratio >5; might be associated with other driver anomalies if definition criteria not strict 
FISH None 
PCR: Polymerase Chain Reaction, FISH: Fluorescent In-Situ Hybridisation 
Table 2.1: Diagnostic tests and molecular targeted therapies based on genetic alterations of lung cancer (Hirsch et al., 2017). 
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2.4 Gene therapy: CRISPR-Cas9 system 
Zinc-finger nucleases (ZFN), transcription activator-like effector nucleases (TALENS), 
and CRISPR-Cas9 system are new methods that have been introduced to manipulate gene 
expression in an in vitro and in vivo models (Gaj, 2013). However, CRISPR-Cas9 system 
is preferable as it is a simple, flexible and more cost-efficient method with an ability to 
produce a stable knockout in different types of cells (Chang et al., 2016). CRISPR-Cas9 
has been shown to be successfully used in gene knockout including in human cell lines, 
mice, zebrafish, Drosophila and Caenorhabditis elegans (Hwang et al., 2013, Mali et al., 
2013, Pépin et al., 2014, Ran et al., 2013). The establishment of this new genetic 
manipulation may lead to a successful gene therapy in the future. CRISPR or clustered, 
regularly interspaced, short palindromic repeats - associated (Cas) systems is used in 
bacteria to silence foreign nucleic acids (Hwang et al., 2013). CRISPRs are DNA loci 
with short repetitions of base sequences (Marraffini and Sontheimer, 2010). Short 
segments of “spacer DNA” are present in between each repetitions from previous 
exposures to a virus (Marraffini and Sontheimer, 2010).  
 
There are three types of CRISPR system (I – III), each containing different subtypes.  
Each system comprises  a cluster of CRISPR-related (Cas) genes, noncoding RNAs and 
a distinctive direct repeats of arrays (Ran et al., 2013). The process and transcription of 
the repeat-spacer array forms the accumulation of small CRISPR RNAs (crRNAs) 
containing a full or partial sequence (Bikard and Marraffini, 2013). crRNAs play a role 
to guide the Cas9 ribonucleoprotein complex to the protospacers, a short variable 
sequence on the exogenous DNA targets (Bikard and Marraffini, 2013, Ran et al., 2013, 
Gottesfeld et al., 1997). Within the DNA targets sequences, each protospacer always 
accompanied with a protospacer adjacent motif (PAM), which is different in differing 
CRISPR-Cas9 systems (Marraffini and Sontheimer, 2010, Bikard and Marraffini, 2013, 
Barrangou et al., 2007, Brouns et al., 2008). Type II CRISPR system consists of nuclease 
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Cas9, the trans-activating crRNA (tracrRNA) and a small RNA antisense to the repeat 
sequence. Each crRNA unit contains 20-nucleotide (nt) guide sequence and a partial 
direct repeat which guide Cas9 to a 20-base pair (bp) DNA target (Ran et al., 2013). The 
crRNA and tracrRNA can be merged together forming a chimeric, single guide RNA 
(sgRNA) (Ran et al., 2013). Different Cas9 orthologs may have different PAM site 
(Makarova et al., 2011). Cas9 scans region which is complementary between the 
sgRNA to the double stranded DNA (dsDNA) genome of the invader (Bikard and 
Marraffini, 2013). Cas9 then introduces dsDNA cleavage using two independent 
nuclease domains (RuvC and HNH) on each of the DNA strand (Bikard and Marraffini, 
2013). As the CRISPR system used in this study was derived from Streptococcus 
pyogenes, the target DNA must immediately precede a 5′-NGG-3′ PAM site for cleavage 




Figure 2.3: Cas9 causing  dsDNA breaks on both strands of the genome targeting based 
on sgRNA sequence in type II CRISPR-Cas9 system with the presence of 5′-NGG-3′ 
PAM site on targeted dsDNA (Bikard and Marraffini, 2013). 
 
Cas9 decrease the off-target effect as it is highly specific, efficient and well-suited for 
high throughput and multiple gene editing for different cell types and organisms (Ran et 
al., 2013, Mali et al., 2013). This double-nicking strategy using CRISPR-Cas9 approach 
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has successfully generate stable knockout cell line models in human (Pépin et al., 2014, 
Mali et al., 2013). Recently, CRISPR-Cas9 system has been effectively used for knockout 
AKRIBI gene expression in human endometrial cell lines (Pépin et al., 2014). Previously, 
Mali et al., (2013) has also shown the use of CRISPR-Cas9 as a tool in gene editing in 
human cell line by engineering the CRISPR system of type II bacterial to function with 
custom gRNA in human cells (Mali et al., 2013). CRISPR-Cas9 systems will ease the 
efficacy of human editing. Thus, in this study CRISPR-Cas9 systems is used to increase 
the understanding of regulation and function of miR130a in NSCLC cell line. 
Consequently, these models can be carried out in human tissues and complement animal 
studies for future studies. Thus, the application of CRISPR-Cas9 system in gene therapy 
need to be extensively studied at in vitro and in vivo level first which can eventually 
benefit not only to treat cancer but for other diseases as well.  
 
2.5 miRNA as a target gene for therapy 
Several studies reported that microRNA (miRNA) expression profiles and specific 
miRNAs were able to distinguish between better-prognosis and worse-prognosis of lung 
cancers (Torre et al., 2015). As miRNAs circulates in the body fluids, they may serve as 
promising biomarkers for early diagnosis and predicting prognosis of lung cancers (Torre 
et al., 2015). Thus, in this study, miRNA was used as target gene for CRISPR-Cas9 
system. miRNAs are short stranded noncoding RNA of ~22 nucleotides that participates 
in various human biological activities such as regulation of apoptosis, cell proliferation, 
cellular differentiation, development and immune responses (He and Hannon, 2004). 
miRNA were firstly discovered because of their roles in controlling the timing of larvae 
development in Caenorhabditis elegans (Hurst et al., 2009). Later, it was then discovered 
in plant and mammalian cells (Filipowicz et al., 2008). To date, 2588 of mature human 
miRNAs have been identified (Kozomara and Griffiths-Jones, 2014) and the expression 
pattern of these miRNAs are regulated both spatially and temporally in the cells (Jeong 
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et al., 2014, Ziu et al., 2014). These miRNAs can be found in tissue as well as in the 
circulating peripheral blood, and predicted to control various metabolic pathways, 
regulate differentiation of stem cells and maintain biological homeostasis (Liu et al., 
2013, Vasanthan et al., 2015, Yong et al., 2015). In cancer cells, several studies have 
shown that some miRNAs have an ability to distinguish malignant cancer cells from 
normal and play a role in the carcinogenesis development in cancer patients giving high 
hope to use miRNAs as therapeutic target for diagnosis, prognosis and treatment of cancer 
(Li et al., 2008, Wang et al., 2014, Nurul-Syakima et al., 2011, Chen et al., 2009). 
 
2.5.1 Silencing of miRNA in vitro 
miRNA loss-of-function studies have been employed to manipulate the expression of 
miRNA. Three general approaches in silencing miRNAs are genetic knockouts, miRNA 
sponges and antisense oligonucleotides (Table 2.2) (Meister et al., 2004, Krützfeldt et al., 
2005, Ørom and Lund, 2010). Generation of miRNA gene knockouts has extensively 
revealed on the functions of miRNAs in C. elegans and Drosophila and more than 476 
miRNAs in mouse (Williams et al., 2009, van Rooij et al., 2009, Sokol and Ambros, 2005, 
Abbott et al., 2005, Miska et al., 2007, Johnnidis et al., 2008, Ventura et al., 2008, Van 
Rooij et al., 2008, Mu et al., 2009). miRNA sponge consists of a numbers of target sites 
which complement to target miRNA (Ebert and Sharp, 2010). It then specifically silences 
the activity of a family of miRNAs with a common seed both in transient and long-term 
inhibition (Stenvang et al., 2012). AntimiR oligonucleotides is the first modified antisense 
oligonucleotides that has been demonstrated to work in mammals (Broderick and Zamore, 
2011). AntimiR oligonucleotides composed of 2́ -O-methyl-modified ribose sugars, 
terminal phosphorothioates and at the 3́ end cholesterol group which assist in the delivery 
of antimiR to cells (Broderick and Zamore, 2011). Later, locked nucleic acid (LNA), an 
alternative modified technology has been introduced into the 2́ -O-methyl- modified 
ribose sugars structure (Broderick and Zamore, 2011). LNA addition to the structure 
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increases the binding affinity to target miRNA and are more resistant to degradation 
(Broderick and Zamore, 2011). However, miRNA sponges and antimir oligonucleotides 
are difficult to synthesis, costly and causes toxic side-effects which limit on the 
application (Kluiver et al., 2012, Garzon et al., 2010).  Thus, in this study, CRISPR-Cas9 
system was employed to silence on the expression on miRNA as it is a simple, flexible 
and more cost-efficient method in generating a stable transfection. 
 
Table 2.2: Strategies to silence miRNA activity (Stenvang et al., 2012). 
Technology Characteristics In vitro 
Genetic knockout Constitutive or 
conditional 
Primary cells 
miRNA sponges Transient to long-term Transfection or viral delivery 
antimiR 
oligonucleotides 
Transient (in vitro) to 
long-lasting inhibition 




2.52 Biogenesis of miRNA 
The miRNAs post-transcriptionally regulate the expression of protein-coding genes by 
binding to the specific binding sites in their 3' untranslated region (UTR) and cause either 
mRNA degradation or translational termination (Bartel, 2004). There is a scarce 
knowledge about the transcription regulation of primary-miRNAs (pri-miRNA). 
However, a study showed that certain pri-miRNA is sited in the introns of host genes for 
both protein-coding genes and non-coding genes (Lagos-Quintana et al., 2003). Thus, it 
may be transcriptionally regulated by their host-gene promoters (Lagos-Quintana et al., 
2003). In nucleus, pri-miRNA is transcribed by RNA polymerase II (Ha and Kim, 2014). 
As shown in Figure 2.4 (a), the pri-miRNA is made up of a stem of 35-35 bp, a terminal 
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loop and single-stranded RNA segments at both 5' and 3' ends (Ha and Kim, 2014). The 
pre-miRNA on the other hand is the product of the cleavage of microprocessor complex 
(Drosha and DGCR8) with ~22 bp at both 5' and 3' ends (Figure 2.4 (b)) (Ha and Kim, 
2014). 
 
Figure 2.4: (a) The structure of pri-miRNA, consisting of 5', 3' end and terminal loop 
(stem loop) and the position of cleavage site by Drosha. (b) The structure of pre-miRNA 
and the cleavage site of Dicer (Ha and Kim, 2014). 
 
Microprocessor complex will recognise and cleaves-off pri-miRNA at the position of 
approximately 11 bp from the basal junction and 22 bp from the apical junction producing 
precursor-miRNA (pre-miRNA) leaving two nucleotides overhang in the 3' end (Krol et 
al., 2010, Ha and Kim, 2014). The pre-miRNA exit the nuclease with the help of exportin 
5 (EXP5) which is a Ran-GTP nucleo/cytoplasmic cargo transporter (Ha and Kim, 2014). 
In the cytoplasm, Dicer cleaves off the stem loop (SL) leaving 3' end (3p) and 5' end (5p) 
as shown in Figure 2.4 (b) (Hutvágner et al., 2001, Ketting et al., 2001). The cleavage 
formed a small, imperfect dsRNA duplex (miRNA:miRNA*) consisting of mature 
miRNA strand and ‘passenger’ strand (miRNA*) (Hutvágner et al., 2001, Ketting et al., 
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2001). One of the dsRNA duplex, preferentially with the  less stable 5' end is assembled 
into the RNA-induced silencing complex (RISC) (Schwarz et al., 2003, Khvorova et al., 
2003). On the other hand, the ‘passenger’ strand will be removed immediately after 
dsRNA duplex is loaded in the pre-RISC complex (Ha and Kim, 2014). The assembling 
of the less stable miRNA strand portrays the ease of unwinding the dsRNA duplex (He 
and Hannon, 2004).  However, if both of the miRNAs in the dsRNA duplex have similar 
5' end stability, it is predicted that both miRNAs have similar frequencies to be 
established into RISC (He and Hannon, 2004, Schwarz et al., 2003). The miRNA-
containing complexes then bind to the 3' UTR of multiple mRNAs as the resident miRNA 
strand and the target sequence are complementary (Arndt et al., 2009, Iorio and Croce, 
2012) causing either translational inhibition or mRNA degradation (Arndt et al., 2009) 
(Figure 2.5). 
 
The choice of targets mRNA being degraded or translationally inhibited is not determined 
by whether the small silencing RNA originated as an small interfering RNA (siRNA) or 
miRNA but instead is determined by the degree of sequence complementarity between 
miRNA and the target mRNA (Billy et al., 2002, Doench et al., 2003).  Perfect 
complementarity results in endonucleocytic cleavage and mRNA degradation while less 
complementarity leads to repression of protein translation (Reinhart et al., 2000, 
Hutvágner et al., 2001). Even though translational repression caused by imperfect 
complementarity seems to be the major mechanism in animals, studies show that several 
animal mRNAs mediated by mRNA degradation despite being partial complementarity 
to miRNAs (Wightman et al., 1993, Billy et al., 2002, Lim et al., 2005). The multiple 
miRNA complementary binding sites have been shown to be the most effective of 
translational inhibition in metazoan miRNAs (Doench et al., 2003, Lee et al., 1993, 





Figure 2.5: miRNA biogenesis and post-transcriptional suppression of miRNA via 
translational repression or mRNA cleavage (He and Hannon, 2004). 
 
2.53 miRNA130a 
The human pre-miR130a (pre-miR130a) with annotation hsa-mir-130a (Accession No. 
MI0000448, Symbol HGNC:MIR130A) (Geer et al., 2009) is located on the chromosome 
11 of homo sapiens at 57641198-57641286. The structure of pre-miR130a is made up of 
5' (15 - GCU CUU UUC ACA UUG UGC UAC U - 36), 3' (55 - CAG UGC AAU GUU 
AAA AGG GCA U - 76) and stem loop strand (36 - GUC UGC ACC UGU CAC UAG - 
55) (Figure 2.6).  The miR130a is a vertebrate-specific miRNA and the sequence of 
mature miR130a-3p are conserved in human, mouse, rat, zebrafish, chicken, clawed frog, 
opossum, dog, wild boar, chimpanzee, cow, horse and others  (Kozomara and Griffiths-
Jones, 2014, Kozomara and Griffiths-Jones, 2011, Griffiths-Jones et al., 2006, Griffiths-
Jones, 2004). The sequence of miR130a-5p is not conserved and is not detected in all 
vertebrates but it is expressed in few vertebrates such as human, mouse, rat, chicken and 
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opossum with slight difference in the sequence (Kozomara and Griffiths-Jones, 2014, 
Kozomara and Griffiths-Jones, 2011, Griffiths-Jones et al., 2006, Griffiths-Jones, 2004). 
Studies showed that miRNAs contribute in the regulation of almost all cellular processes 
and that the changes in their expression observed has been shown to be involved in multi-
step carcinogenesis in cancer (Filipowicz et al., 2008).  As an evidence, bioinformatics 
predictions suggested that miRNA may potentially regulate thousands of genes as 30% 
of  all protein coding genes may be affected by miRNAs (Lewis et al., 2005). The miR-
130a has been reported to be upregulated in several types of cancer, such as colon cancer, 
NSCLC, chronic myeloid leukaemia and hepatocellular carcinoma indicating the 
important roles of miR130a in cancer development, progression and metastasis (Chen et 
al., 2010, Wang et al., 2010, Suresh et al., 2011, Zhou et al., 2012). 
 
 
Figure 2.6: Figure shows the structure of pre-miR130a consisting of 5' (5p) end, stem 
loop and 3' (3p) end (Abdollah et al., 2017). 
 
2.5.4 miR130a expression 
The expression of 3p and 5p of miR130a depends on spatial and temporal control of 
miR130a gene expression in mammalian cells. The expression of miR130a-3p and 5p is 
selectively high or down regulated in different types of cells and tissues. This has been 
supported by a study which shows that the selection of mature miRNA strand depends on 
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cell type, tissue and stimulus (Meijer et al., 2014). The expression of miR130a-3p is down 
regulated in mixed-lineage leukemic cells (Li et al., 2008), lung squamous carcinoma 
(Cao et al., 2016), breast cancer (Pan et al., 2015) and colorectal cancer cells (Kara et al., 
2015). On the other hand, there were less report on the expression of miR130a-5p 
especially in cancer studies. A study reported that the expression of miR130a-5p is down 
regulated in endometrial and endometriotic cells (Braza-Boïls et al., 2015). Another study 
reported that that both miR-130a-3p and 5p are highly expressed in gestational obesity 
(Carreras-Badosa et al., 2015). 
 
miRNA has been shown to be involved whether as oncogene miRNA (oncomiR) or 
tumour suppressor gene in different pathways in cancer. Several studies reported that 
miR130a is an oncomiR as it was highly expressed in cancer including in gastric cancer 
cells and cervical cancer cell (Lee et al., 2015, Zhou et al., 2017, Feng et al., 2016, Zhang 
et al., 2014). In gastric cancer cells, miR130a high expression suppressed the expression 
of dual-luciferase reporter assays, collapsing response mediator protein 4 (CRMP4) gene 
and runt-related transcription factor 3 (RUNX3) which enhanced cell proliferation and 
apoptosis, increases cell colony formation, invasion, migration, and adhesion (Zhou et 
al., 2017, Lee et al., 2015). In cervical cancer, upregulation of miR130a modulates nuclear 
factor-kB (NF-kB) and tumour necrosis factor-alpha (TNF-α) which then target 
phosphatase and tensin homolog on chromosome 10 (PTEN) and leading to increase in 
cell proliferation in carcinogenesis of cancer cells (Zhang et al., 2014, Feng et al., 2016).  
 
On the other hand, miR130a acts as tumour suppressor in lung cancer, breast cancer and 
nasopharyngeal cancer (Lin et al., 2015, Pan et al., 2015, Kong et al., 2018, Chen et al., 
2018, Chen et al., 2017). In lung cancer, a study reported that the suppression of miR130a 
regulates macrophage polarization in NSCLC (Lin et al., 2015). The result showed that 
mir130a acted as a molecular switch as it expresses at higher level in M1 compared to 
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M2 macrophages (Lin et al., 2015). Thus, this study concluded that downregulation of 
miR130a in NSCLC resulted in poor prognosis, increased tumour stage and metastasis 
(Lin et al., 2015). The expression miR130a was shown to be a tumour suppressor in breast 
cancer cell line (Pan et al., 2015). As the expression of miR130a was shown to be 
downregulated, the overexpression of miR130a inhibits cell proliferation, invasion and 
migration of cancer cells by targeting at ras-related protein Rab-5A (RAB5A) and fos-
related antigen 1 (FOSL1) (Pan et al., 2015, Kong et al., 2018). Low expression of 
miR130a-3p inhibits the expression of transcription regulator gene, BACH2 which 
suppressing the viability, proliferation, invasion, cell cycle and promotes apoptosis in 
nasopharyngeal carcinoma cells (Chen et al., 2017).  
 
2.6 Bioinformatics: target gene prediction 
In recent years, many bioinformatics platforms are available to analyse large amount of 
data and to perform comparative analysis of differentially expressed genes. However, 
there is still no one particular and reliable miRNA target prediction platform that can be 
used due to computational challenges, scarce miRNA biology knowledge and the 
inadequate number of experimentally validated target (Betel et al., 2010). As previous 
study has shown that there are differences in the level of miR130a-3p and 5p expression 
in different types of cancer cells, thus there is a need to study the role of miR130a-3p and 
5p in the regulation of tumorigenesis in cancer.  In addition, in this study, the target genes 
for miR-130a-3p and 5p were identified using combinatorial analysis in miRWalk 
database. The target genes were then grouped based on function of miR-130a in non-
small cell lung cancer (gene ontology and Kyoto Encyclopaedia of Genes and Genomes 
(KEGG) analysis) and the result were integrated with the mirSVR score for each 




In this study, miRWalk database is used as it is able to combine few databases in order to 
predict the target genes (Dweep et al., 2014). miRWalk database gathers validated 
information on miRNA binding sites and also predicts on miRNA and target gene 
interactions (Dweep et al., 2014). In addition, the validated target gene is updated every 
month and the predicted target gene is updated for every six months (Dweep et al., 2014). 
It is important to note that this database shows not only the interaction on the 3' - UTR, 
but it also includes the other regions of all known genes of the validated target genes 
(Dweep et al., 2014). Four bioinformatics platforms were used in this study namely 
miRWalk, the DAVID gene functional classification tool, miRanda-miRSVR analysis 
tool for gene prediction of miR130a-3p and 5p, and STRING database and protein-protein 
interaction analysis. DAVID gene functional classification tool is a bioinformatics 
resource that organised and condensed a list of genes into gene functional groups and 
classification of genes based on bio-pathways (Huang et al., 2009). miRanda-miRSVR 
analysis tool on the other hand use the miRanda-predicted miRNA target sites and ranked 
the them by a down regulation score via mirSVR. This method helps to identify large 
numbers of experimentally determined non-canonical and non-conserved sites (Betel et 
al., 2010). Then, the efficiency of miRanda-predicted miRNA target sites will be scored 
and ranked by miRSVR (Betel et al., 2010). Lastly, STRING database will be used to 
predict the protein-protein interaction between the predicted target. The STRING 
database collect and integrate all functional interactions between expressed protein by 
merging experimented and predicted protein-protein association data in different types of 
organisms (Szklarczyk et al., 2016). Thus, the bioinformatics analyses were carried out 
to predict the target genes of miR130a, which will help to understand the function of 
miR130a and how it interacts with genes identified in associated pathways.  
 
 
 
